## 1 To what extent do we need to rely on non-pharmaceutical interventions while

#### 2 COVID-19 vaccines roll out in 2021?

- 3
- 4 Juan Yang<sup>1,2</sup>\*, Valentina Marziano<sup>3</sup>\*, Xiaowei Deng<sup>1</sup>, Giorgio Guzzetta<sup>3</sup>, Juanjuan
- 5 Zhang<sup>1,2</sup>, Filippo Trentini<sup>3</sup>, Jun Cai<sup>1</sup>, Piero Poletti<sup>3</sup>, Wen Zheng<sup>1</sup>, Wei Wang<sup>1</sup>, Qianhui
- 6 Wu<sup>1</sup>, Zeyao Zhao<sup>1</sup>, Kaige Dong<sup>1</sup>, Guangjie Zhong<sup>1</sup>, Cécile Viboud<sup>4</sup>, Stefano Merler<sup>3†</sup>,
- 7 Marco Ajelli<sup>5,6†</sup>, Hongjie Yu<sup>1,2,7†</sup>
- 8
- 9 1. Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health,
- 10 Fudan University, Shanghai, China
- 11 2. Fudan University, Key Laboratory of Public Health Safety, Ministry of Education,
- 12 Shanghai, China
- 13 3. Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
- 14 4. Division of International Epidemiology and Population Studies, Fogarty
- 15 International Center, National Institutes of Health, Bethesda, MD, USA
- 16 5. Department of Epidemiology and Biostatistics, Indiana University School of
- 17 Public Health, Bloomington, IN, USA
- 18 6. Laboratory for the Modeling of Biological and Socio-technical Systems,
- 19 Northeastern University, Boston, MA, USA
- 20 7. Department of infectious diseases, Huashan Hospital, Fudan University, Shanghai,
- 21 China
- 22

- 23 \*These authors contributed equally to this work.
- <sup>†</sup>These authors are joint senior authors contributed equally to this work.
- 25
- 26 Corresponding authors: Marco Ajelli, Department of Epidemiology and Biostatistics,
- 27 Indiana University School of Public Health, 47405 Bloomington, IN, USA; E-mail:
- 28 marco.ajelli@gmail.com, and Hongjie Yu, , Shanghai Institute of Infectious Disease
- and Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China
- 30 E-mail: yhj@fudan.edu.cn
- 31
- 32 Word count (main text): 4,928
- 33 Word count (abstract): 148

# 34 Abstract

35	COVID-19 vaccination is being conducted in over 190 countries/regions to control
36	SARS-CoV-2 transmission and return to a pre-pandemic lifestyle. However,
37	understanding when non-pharmaceutical interventions (NPIs) can be lifted as
38	immunity builds up remain a key question for policy makers. To address it, we built a
39	data-driven model of SARS-CoV-2 transmission for China. We estimated that to
40	prevent the escalation of local outbreaks to widespread epidemics, stringent NPIs
41	need to remain in place at least one year after the start of vaccination. Should NPIs
42	alone be capable to keep the reproduction number $(\mathbf{R}_t)$ around 1.3, the synergetic
43	effect of NPIs and vaccination could reduce up to 99% of COVID-19 burden and
44	bring $R_t$ below the epidemic threshold in about 9 months. Maintaining strict NPIs
45	throughout 2021 is of paramount importance to reduce COVID-19 burden while
46	vaccines are distributed to the population, especially in large populations with little
47	natural immunity.

48	The novel coronavirus disease 2019 (COVID-19) pandemic is far from over with
49	cases still surging in many countries across the globe, particularly with India suffering
50	from a catastrophic second wave <sup>1</sup> . In 2020, epidemic suppression and/or mitigation
51	have relied on non-pharmaceutical interventions (NPIs), including social distancing,
52	school closure, masking, and case isolation. Although effective and widely adopted to
53	limit SARS-CoV-2 transmission and reduce COVID-19 burden, these interventions
54	entail enormous economic costs and negatively affect quality of life <sup>2</sup> . Additionally, in
55	many countries, relaxation of NPIs has led to a resurgence of the epidemic as herd
56	immunity has not been reached thus far $^3$ .
57	
58	Effective vaccines against COVID-19 remain the only foreseeable means of both
59	suppressing the infection and returning to pre-pandemic social and economic activity
60	patterns. Globally, several vaccines have been licensed, and vaccination programs
61	have been initiated in more than 190 countries/regions, including China <sup>4</sup> . However,
62	the projected global production and delivery capacities are likely to be inadequate to
63	provide COVID-19 vaccines to all individuals who are still susceptible to
64	SARS-CoV-2 infection <sup>3</sup> . The effectiveness of COVID-19 vaccination campaigns will
65	depend on several factors, including pre-existing immunity, vaccine supply,
66	willingness to receive the vaccine, and strategies for vaccine allocation and
67	deployment <sup>5</sup> .
68	

69 To avoid widespread transmission of SARS-CoV-2, since the end of the first

70	COVID-19 wave in the spring of 2020, China has implemented strict NPIs and has
71	successfully controlled local outbreaks, preventing a second widespread wave of
72	COVID-19. Since December 2020, China has given conditional approval for the use
73	of four COVID-19 vaccines and emergency use approval for one. As of May 7, 2021,
74	308 million doses (corresponding to 10.7% of the population) have been administered
75	<sup>6</sup> . However, such a coverage is still extremely low and thus China remains highly
76	vulnerable to importations of SARS-CoV-2 and onward transmission, as proved by
77	several local outbreaks that occurred in the first four months of 2021, the largest of
78	which occurring in Heilongjiang province led to 659 reported cases and spilled over
79	to a neighboring province (419 cases were reported in Jilin) <sup>7</sup> . At present, estimating
80	whether and when NPIs can be lifted, and the extent to which we need to rely on NPIs
81	while vaccines roll out represents a top priority for policy making.
82	
83	This question has not been well addressed in China, one of the few countries in the
84	world where nearly the entire population is still susceptible to SARS-CoV-2 infection,
85	and home to almost 1.4 billion individuals (roughly 18% of the world population). To
86	fill this gap, we built on top of the wide body of work adopting mathematical models
87	of the infection transmission process to evaluate vaccination programs <sup>8-12</sup> . In
88	particular, we developed an age-structured stochastic model to simulate SARS-CoV-2
89	transmission triggered by cases imported in mainland China, based on a
90	susceptible-infectious-removed (SIR) scheme (Supplementary Fig.1). We consider a

91 situation in which: i) no ongoing widespread SARS-CoV-2 transmission, ii) nearly no

92	immunity in the population, and iii) high risk of importing SARS-CoV-2 infected
93	individuals, possibly leading to an upsurge of COVID-19 cases. Since COVID-19
94	vaccines are expected to continue rolling out throughout 2021-2022, we consider also
95	alternative scenarios where SARS-CoV-2 infections leading to an outbreak are
96	imported when 10% (close to the coverage as of May 2021), 20%, and 30% of the
97	Chinese population has already been vaccinated (according to the simulated
98	vaccination program).
99	
100	In the model, we account for heterogeneous mixing patterns by age <sup>13</sup> and progressive
101	vaccine deployment among different population segments based on a priority scheme
102	(essential workers, older adults and individuals with underlying conditions, etc.) $^{14}$ .
103	Further, we overlay a disease burden model on the transmission model to estimate the
104	number of symptomatic cases, hospitalizations, ICU admissions, and deaths under
105	different vaccination scenarios and based on empirical data <sup>15-20</sup> . The resulting
106	integrated model is informed by data on COVID-19 natural history, age-mixing
107	patterns specific to China quantified during the pre-pandemic period, and the size of
108	the different vaccination targets in the Chinese population (e.g., individuals with
109	pre-existing conditions). A qualitative model description is reported in the Methods
110	section, a summary of model parameters and data sources is reported in
111	Supplementary Table 1, all other details are reported in Supplementary File 1-5.
112	The combined effect of NPIs and vaccination programs are evaluated in terms of their
113	ability in reducing the disease burden caused by outbreaks arising from possible

# 114 importation of cases.

115

116	We considered a baseline vaccination scenario where: 1) vaccination starts 15 days
117	after an outbreak triggered by 40 breakthrough imported SARS-CoV-2 infections; 2)
118	vaccine efficacy (VE) against SARS-CoV-2 infections for a two-dose schedule (with a
119	21-day interval) is set at 80% $^{21}$ ; 3) vaccination coverage is capped at 70% across all
120	ages <sup>14</sup> ; 4) 6 million doses are administered daily (4 per 1,000 individuals, informed
121	by the ongoing COVID-19 vaccination program <sup>6</sup> , and estimates of vaccine supply till
122	2021 in China <sup>22-26</sup> ); 5) the first priority target consists of older adults and individuals
123	with underlying conditions (descriptions in details shown in Supplementary Table 2);
124	6) there is no prior population immunity from natural infection, which aligns with the
125	situation in most of China where there has been little circulation of SARS-CoV-2 as
126	of May 2021 <sup>3</sup> ; 7) we assume an initial reproductive number $R_t = 2.5$ at the start of the
127	outbreak <sup>27-32</sup> , in the absence of NPIs and vaccination; 8) Children under 15 years of
128	age were considered to have a lower susceptibility to SARS-CoV-2 infection as
129	compared to adults (i.e., individuals aged 15 to 64 years), while individuals aged 65+
130	years had the highest susceptibility to infection (Supplementary Table 1) $^{33,34}$ ; and 9)
131	we let the model run for two years. To evaluate the impact of the baseline assumptions
132	on our results, we conduct comprehensive sensitivity analyses (SA).
133	

134Results

135 Main analysis

136	In the absence of NPIs, the vaccination program is too slow to lower and delay the
137	epidemic (Fig. 1a) and does not effectively reduce COVID-19 burden. $R_t$ falls below
138	the epidemic threshold (<1) 69 days after the epidemic start (Fig. 1b), but this is
139	primarily attributable to immunity gained through natural infection rather than
140	vaccination. Indeed, in this time frame, 52.2% of population gets infected, while only
141	6.7% of population has been vaccinated (Fig. 1c). The cumulative number of
142	symptomatic cases and deaths over a 2-year period only decrease by 3.3% (95%CI,
143	3.1%-4.7%) and 6.7% (95%CI, 4.5%-8.9%), respectively, as compared to a reference
144	scenario where there is no vaccination and no NPIs, which would lead to 306.73
145	million (95%CI, 282.68-320.60) symptomatic cases, 99.25 million (95%CI,
146	92.55-104.51) hospitalizations, 7.19 million (95%CI, 6.00-7.83) ICU admissions, and
147	9.38 million (95%CI, 7.70-10.26) deaths (Fig. 2).
148	
149	
	Provided that NPIs are in place and can keep $R_t$ at 1.3 in the absence of vaccination
150	Provided that NPIs are in place and can keep R <sub>t</sub> at 1.3 in the absence of vaccination ( <i>moderate NPIs scenario</i> ), the vaccination program could reduce COVID-19 burden
150 151	Provided that NPIs are in place and can keep R <sub>t</sub> at 1.3 in the absence of vaccination ( <i>moderate NPIs scenario</i> ), the vaccination program could reduce COVID-19 burden by about 99% compared to the <i>reference no-vaccination scenario</i> , with 5.46 million
150 151 152	Provided that NPIs are in place and can keep R <sub>t</sub> at 1.3 in the absence of vaccination ( <i>moderate NPIs scenario</i> ), the vaccination program could reduce COVID-19 burden by about 99% compared to the <i>reference no-vaccination scenario</i> , with 5.46 million (95%CI, 2.47-13.36) symptomatic cases, 1.77 million (95%CI, 0.83-4.40)
150 151 152 153	Provided that NPIs are in place and can keep R <sub>t</sub> at 1.3 in the absence of vaccination ( <i>moderate NPIs scenario</i> ), the vaccination program could reduce COVID-19 burden by about 99% compared to the <i>reference no-vaccination scenario</i> , with 5.46 million (95%CI, 2.47-13.36) symptomatic cases, 1.77 million (95%CI, 0.83-4.40) hospitalizations, 73,500 (95%CI, 7,300-152,100) ICU admissions, and 76,700
150 151 152 153 154	Provided that NPIs are in place and can keep R <sub>t</sub> at 1.3 in the absence of vaccination ( <i>moderate NPIs scenario</i> ), the vaccination program could reduce COVID-19 burden by about 99% compared to the <i>reference no-vaccination scenario</i> , with 5.46 million (95%CI, 2.47-13.36) symptomatic cases, 1.77 million (95%CI, 0.83-4.40) hospitalizations, 73,500 (95%CI, 7,300-152,100) ICU admissions, and 76,700 (95%CI, 8,200-165,700) deaths (Fig. 2). In this context, vaccination decreases
150 151 152 153 154 155	Provided that NPIs are in place and can keep R <sub>t</sub> at 1.3 in the absence of vaccination ( <i>moderate NPIs scenario</i> ), the vaccination program could reduce COVID-19 burden by about 99% compared to the <i>reference no-vaccination scenario</i> , with 5.46 million (95%CI, 2.47-13.36) symptomatic cases, 1.77 million (95%CI, 0.83-4.40) hospitalizations, 73,500 (95%CI, 7,300-152,100) ICU admissions, and 76,700 (95%CI, 8,200-165,700) deaths (Fig. 2). In this context, vaccination decreases COVID-19 burden by about 40% (Fig. 2) compared to a situation with moderate NPI
150 151 152 153 154 155 156	Provided that NPIs are in place and can keep Rt at 1.3 in the absence of vaccination (moderate NPIs scenario), the vaccination program could reduce COVID-19 burden by about 99% compared to the reference no-vaccination scenario, with 5.46 million (95%CI, 2.47-13.36) symptomatic cases, 1.77 million (95%CI, 0.83-4.40) hospitalizations, 73,500 (95%CI, 7,300-152,100) ICU admissions, and 76,700 (95%CI, 8,200-165,700) deaths (Fig. 2). In this context, vaccination decreases COVID-19 burden by about 40% (Fig. 2) compared to a situation with moderate NPI alone, and Rt falls below the epidemic threshold about 9 months after the epidemic

158	population would have been vaccinated, while 0.8% would have been naturally
159	infected (Fig. 1g-i). This highlights that a relevant proportion of the population would
160	be still susceptible to SARS-CoV-2 at that time. Although in the long-term
161	vaccination can ultimately lead to the suppression of transmission, it is necessary to
162	maintain NPIs for one year after the onset of vaccination. Indeed, if NPIs are relaxed
163	from moderate ( $R_t$ =1.3) to mild ( $R_t$ =1.5) 9 months after vaccination start, the
164	cumulative death toll could increase from 76,700 to 173,000. In contrast, a small
165	increase in cumulative deaths from 76,700 to 81,700 is expected if this relaxation
166	occurs one year after vaccination start, while earlier or more drastic relaxations of
167	NPIs lead to substantial increases in deaths (Extended Data Fig.1-3).
168	
169	A combination of more stringent NPIs (i.e., capable of keeping $R_t = 1.1$ ) and
170	vaccination ( $vax + high NPIs$ scenario) could suppress the epidemic, with <2,300
171	symptomatic cases, and <50 deaths on average. Although the majority of the
172	reduction of COVID-19 burden is ascribable to NPIs in this case (over 85%), the
173	deaths averted due to vaccination are about 1.2 million (Fig. 1j-l, and Fig. 2).
174	
175	If we consider a set of mild NPIs (vax + mild NPIs scenario), even a relatively low
176	initial reproduction number under NPIs of $R_t$ =1.5 could still lead to a disastrous
177	epidemic, with nearly two million deaths. Despite the high death toll of the resulting
178	epidemic, NPIs and vaccination would jointly reduce around 80% of the disease
179	burden compared to a scenario with no NPIs and no vaccination (namely, 239 million

180 symptomatic cases and 8.2 million deaths averted) (Fig. 1d-f, and Fig. 2).

181

## 182 Vaccine distribution capacity

- 183 Should the daily vaccination rollout be limited to 1.3 million doses (1 per 1,000
- 184 individuals a slower rate than during the 2009 H1N1 pandemic), vaccination would
- 185 not effectively reduce COVID-19 related deaths unless there was adoption of
- stringent NPIs. In a scenario where vaccination capacity reaches 10 million doses
- administered per day (7 per 1,000 individuals), vaccination would reduce COVID-19
- related deaths to <5,000 for moderate NPIs and <30 for high NPIs. Should the daily
- 189 vaccination capacity be increased to 15 million doses (10 per 1,000 individuals),
- 190 vaccination could effectively reduce deaths to <100,000 (similar to the annual
- 191 influenza-related death toll in China<sup>35</sup>) even in the presence of mild NPIs. However,
- 192 even if the daily vaccination capacity could be increased to 30 million doses (20 per
- 193 1,000 individuals), in the absence of NPIs, we estimate that over 7.7 million deaths
- 194 would still occur (Fig. 3). Similar patterns are estimated for the number of
- symptomatic cases, hospitalizations and ICU admissions (Extended Data Fig.4-6).

196

- 197 Increasing daily vaccination capacity could largely shorten the time needed to control
- 198 SARS-CoV-2 transmission. For instance, when considering a daily capacity of 10
- 199 million and 15 million doses and moderate NPIs, Rt would drop below 1 about 8 and
- 200 6 months respectively after epidemic onset (to be compared to the 9.3 months
- estimated with the baseline capacity of 6 million doses). At that time, over 60% of the

202	population would be vaccinated and $\leq 0.1\%$ would be naturally infected. An upscale in
203	the daily capacity to 10 or 15 million doses would allow a relaxation of NPIs from
204	moderate to mild already 6 to 9 months after vaccination start, i.e., 3 to 6 months
205	earlier with respect to the baseline. On the other hand, more drastic relaxations of
206	NPIs (e.g., from moderate to no NPIs) would still lead to substantial increases in
207	symptomatic cases and deaths (Extended Data Fig.7-10).
208	
209	Vaccination prioritization
210	We consider alternative vaccination scenarios that prioritize essential workers (staff in
211	the healthcare, law enforcement, security, community services, and individuals
212	employed in cold chain, etc.) to maintain essential services and then explore different
213	prioritization strategies for the rest of the population. Our results suggest that the
214	relative timing of the epidemic and of the vaccination rollout play a key role in
215	determining the most effective strategy. In particular if we consider vaccination to
216	start two weeks after 40 cases are detected, there is no clear prioritization strategy that
217	minimize deaths, as the outcome of the vaccination campaign heavily depends on the
218	timing at which the epidemic unfolds (Fig. 4 and Extended Data Fig. 11-12). Instead,
219	if the epidemic is already underway when the vaccination campaign starts (>5,000
220	cases), prioritizing working-age groups minimizes the number of deaths when $R_t \le 1.3$ .
221	In contrast, prioritizing older adults and individuals with underlying conditions is
222	more effective when $R_t \ge 1.5$ (direct benefits are higher, Fig. 4 and Extended Data Fig.
223	11-12). Two results are independent of the adopted prioritization strategy: i) if $R_t \ge 1.5$ ,

- then an epidemic cannot be avoided; and ii) when  $R_t = 1.1$ , over 99% of deaths can be
- averted (Extended Data Fig. 11-12).
- 226

## 227 **Population immunity at the onset of an outbreak**

- In December 2020, vaccination has started in China, while measures to detect
- 229 imported cases and case surveillance are in place. The number of doses distributed per
- 230 day has changed over time, following an increasing trend and with a daily average of
- about 6 million doses over the period April 20 May 7, 2017 (Supplementary File 3).
- As of May 7, 2021, the vaccination coverage is 10.7%<sup>6</sup>. The effectiveness of the
- 233 vaccination program and NPIs in preventing new COVID-19 outbreaks and limiting
- 234 COVID-19 burden will thus depend on the level of vaccine-induced immunity in the
- population should an outbreak of locally transmitted cases start to unfold.
- 236
- 237 To simulate this situation, we initialize the model by considering different fractions of
- vaccinated population (SA1: 10%; SA2: 20%; SA3: 30%) at the time the infection is
- seeded. Given a certain level of NPIs in the absence of immunity, increasing
- 240 proportions of vaccinated individuals will decrease the effective reproduction number
- 241 (e.g.,  $R_t = 1.1$  in the absence of immunity, corresponds to  $R_t$  below the epidemic

threshold if 10% or more of the population has been vaccinated).

243

Should 30% of the population already been vaccinated before the start of a new wave,

continuing the vaccination program while adopting mild NPIs would reduce the death

toll by 98% (42,400 deaths as compared 1.8 million if no one was vaccinated).

247	However, in the absence of NPIs, even if 30% of population was already vaccinated
248	before the start of a new wave, carrying on with the vaccination program alone would
249	not be enough to prevent a widespread epidemic leading to 6 (95%CI: 4-7) million
250	deaths (Extended Data Fig.13).
251	
252	Vaccination coverage
253	No significant difference in willingness-to-vaccination between age groups has been
254	reported in China <sup>36-38</sup> . Accordingly, we use a homogenous vaccine coverage of 70%
255	among all age groups in the main analysis. Here we present the results of a set of
256	sensitivity analyses assuming vaccination coverage of 50% (SA4) and 90% (SA5)
257	among all age groups, and considering heterogeneous coverages by age: 1) 70% for
258	adults $\geq$ 20 years and 50% for younger individuals ( <i>SA6</i> ); 2) 90% for adults $\geq$ 20 years
259	and 70% for younger individuals (SA7); 3) 70% for adults $\geq$ 20 years and no
260	vaccination for younger individuals (SA8).
261	
262	By considering moderate NPIs ( $R_t$ =1.3) and a vaccination coverage of 50% in all age
263	groups, the number of symptomatic is estimated to decrease by 33% with an 8%

264 decrease of the death toll with respect to the baseline vaccination scenario (70%

- coverage) (Extended Data Fig.14-15). In fact, the lower coverage in older age groups
- would lead to an earlier vaccination in younger age groups who are characterized by
- the highest contact rates <sup>13</sup>. Conversely, increasing the coverage to 90% would

268	decrease the death tolls but lead to an increase of symptomatic cases (Extended Data
269	Fig.14-15). It is important to remark that these results consider that moderate NPIs
270	remain in place over the entire duration of the epidemic, and they do not provide
271	indications of the coverage needed to suppress any further resurgences of cases.
272	
273	As compared to the baseline vaccination scenario (70% vaccination coverage in all
274	age groups), if the vaccine is not distributed among individuals aged less than 20
275	years, we estimate an increase of the death toll of 69% and of symptomatic infections
276	of 55% (Extended Data Fig.14-15). The scenario assuming 90% vaccination coverage
277	for adults $\geq$ 20 years and 70% for younger individuals lead to a lower reduction of
278	COVID-19 burden as compared with the baseline vaccination scenario (Extended
279	Data Fig. 14-15). The higher coverage in the adult population result in a delayed start
280	of vaccination of the young population, which is characterized by higher contacts
281	rates <sup>13</sup> . Nonetheless, it is important to remark that this result depends on the timing of
282	the introduction of the initial seeds (see previous section).
283	
284	Vaccine efficacy

285 Three types of COVID-19 vaccines are currently in use in China, including

286 inactivated, recombinant protein subunit, and adenovirus-vectored vaccines. VE for

- these vaccines ranges from 65% to 90%, with the exception of the one tested in Brazil
- where P1 variant is prevalent (VE=50%)  $^{39-43}$ . With respect to an 80% VE adopted in
- the baseline scenario, by considering VE=60% (SA9) we estimate a 1.02-fold increase

290 of the death toll and 1.64-fold increase of symptomatic cases. Whereas a 3/% at	ind 29	1%
---	--------	----

- 291 decrease of deaths and symptomatic cases, respectively, is estimated for VE=90%
- 292 (*SA10*). (Extended Data Fig.14-15)
- 293

#### 294 SARS-CoV-2 variants

- 295 Multiple SARS-CoV-2 variants have been documented globally, three of which are of
- 296 particular concern: lineage B.1.1.7 identified in UK, B.1.351 in South Africa, and P.1
- in Brazil  $^{44}$ . These variants are estimated to have higher transmissibility  $^{45,46}$  and
- 298 possibly an increased mortality <sup>47,48</sup>. To assess the effect of vaccination in this context,
- 299 we consider higher values of  $R_t$  (i.e., 1.7, 1.9, and 2.1 about 30%-60% increased
- 300 transmissibility with respect to the main analysis <sup>45</sup>) to account for enhanced
- transmissibility, and use a mean death hazard ratio of 1.64 to account for higher
- 302 mortality <sup>47</sup>. With the assumption of VE=80% against the new variant, COVID-19
- 303 burden substantially increases, compared to the scenario based on the historical
- lineage. The number of symptomatic cases increase from 2 thousand to 173 million,
- and death increase from <50 to 7 million even when strict NPIs are implemented
- 306 (Extended Data Fig. 16).
- 307

## 308 Alternative vaccination parameters and scenarios

309 A further set of sensitivity analyses are conducted to evaluate the impact of baseline

- assumptions on our results for  $R_t=1.3$  (moderate NPIs). Provided that vaccination can
- 311 only protect against illness (SA11) but not SARS-CoV-2 infections, COVID-19 related

312	deaths increase by 33 folds with respect to the baseline: from 76,700 to 2.66 million
313	(Extended Data Fig.14). In this case, maintaining stringent NPIs measures in place for
314	a prolonged time horizon would be necessary as such vaccine would not be effective
315	to suppress transmission (as reported in previous studies <sup>49</sup> ). Assuming a shorter
316	duration of vaccine-induced protection of 6 months (SA12) instead of a lifelong
317	protection (i.e., longer than the 2-year time horizon considered, Extended Data Fig.14)
318	has a similarly large effect on projections.
319	
320	In our main analysis, we use the contact matrix estimated from a contact survey
321	conducted in Shanghai before the COVID-19 pandemic <sup>13</sup> . Should a new COVID-19
322	wave start to unfold in China, it is unclear to what extent pre-pandemic contact
323	patterns could be representative of such a situation. Therefore, we have added a
324	sensitivity analysis where we assume the mixing patterns estimated in Shanghai in
325	March 2020 $^{50}$ , when schools were still closed as a response to the COVID-19
326	pandemic (SA13). For $R_t=1.3$ and the baseline parameters for the vaccination, the
327	estimated number of deaths would be 16,000 as compared to 76,700 estimated using
328	the pre-pandemic mixing patterns (79% decrease, see Extended Data Fig.14). In fact,
329	the relative contribution of the adult population (which is the main target of the
330	vaccination campaign) to the overall transmission as compared to children is higher
331	than when considering pre-pandemic mixing patterns (when schools were open and
332	school-age individuals had the highest number of contacts).

333

334	Other factors such as excluding detected symptomatic cases from vaccination (SA14
335	and SA15), the time interval between two doses (SA16 and SA17), and assuming an
336	all-or-nothing vaccine (SA18), do not substantially affect estimates of deaths and
337	symptomatic infections (Extended Data Fig.14-15). A similar trend is observed for
338	hospitalized cases and ICU admissions.
339	
340	Discussion
341	Using a stochastic dynamic model of SARS-CoV-2 transmission and COVID-19
342	burden tailored to the epidemiological situation in China, we find that in the absence
343	of NPIs, and independently of the vaccine prioritization strategy and capacity of the
344	vaccination campaign, timely rollout of an effective vaccine (VE = $80\%$ ) would not be
345	enough to prevent a local outbreak to escalate to a major widespread epidemic.
346	Provided that NPIs are in place and capable to bring $R_t$ to 1.3, a daily vaccine rollout
347	of 4 doses per 1,000 individuals could reduce around 99% of COVID-19 burden, and
348	bring $R_t$ below the epidemic threshold about 9 months after the start of the
349	vaccination campaign. A relaxation of NPIs that bring the value of $R_t$ to 1.5 could not
350	prevent sustained epidemic growth which would cause 1.8 million deaths. A net
351	reproduction number of 1.5 could only be sustained when accompanied by an
352	improvement of the vaccine administration capacity up to 10 doses per 1,000
353	individuals per day. Relaxation of NPIs in the first 6-9 months of vaccine rollout
354	could lead to substantial increases of COVID-19 burden if daily vaccination capacity
355	could not be enhanced to 10-15 million doses.

356

357	Bubar K, et al. evaluated COVID-19 vaccine prioritization strategies and found that
358	prioritizing older adults is a robust strategy to minimize deaths across countries when
359	$R_t$ =1.5, while prioritization shifted to 20-49 years group when $R_t$ =1.15 <sup>51</sup> . The broad
360	scope of that multi-country analysis does not account for features of COVID-19
361	epidemiology and vaccination program that are unique to China. In particular,
362	differently from most countries where natural immunity is building up after
363	widespread epidemics, China has been able to suppress SARS-CoV-2 transmission for
364	most of 2020. As a result, prior immunity is very low, thus calling for specifically
365	tailored analysis. Nonetheless, our findings confirm that if NPIs can maintain
366	transmission rates at low levels during the vaccination campaign, strategies that target
367	indirect benefits perform better, while if transmission rates remain high, strategies
368	maximizing direct benefits may save more lives <sup>51</sup> .
369	
370	As highlighted in vaccination studies in Italy <sup>52</sup> , in the race between the vaccination
371	campaign to build population herd-immunity and the progress of the epidemic, the
372	speed of vaccine deployment is critical. Considering the average vaccine distribution
373	capacity of the current COVID-19 vaccination campaign in China <sup>6</sup> , we use 6 million
374	doses administered per day in the baseline analysis. Several manufacturers state that a
375	total of 3.9 billion doses of COVID-19 vaccine could be produced in 2021, equivalent
376	to about 10 million doses per day <sup>22-26</sup> . China committed to provide COVID-19
377	vaccines to >100 countries, and thus that could reduce the number of doses to be

378	distributed locally. Even if these candidate vaccines could be licensed and
379	manufactured smoothly, it would take about one year to vaccinate 70% of the
380	population.
381	
382	Five months after initiating vaccination program, 10.7% of Chinese population has
383	been vaccinated <sup>6</sup> . Limited vaccine production capacity, particularly at the initial stage,
384	could slow the speed of vaccine rollout. Slower rates of vaccine production and
385	administration may result in a longer period of SARS-CoV-2 transmission. It is thus
386	crucial to keep monitoring local outbreaks and invest resources in outbreak
387	management (as currently done in China) in order to keep $R_t$ close to the epidemic
388	threshold at least for the next 1-2 years. In the very unique context of China, a value
389	of $R_t$ of 1.3 would result in about 76,700 cumulative deaths, comparable to the annual
390	influenza-related death toll in China <sup>35</sup> . The development of detailed logistical plans
391	and tools to support an increased vaccination capacity as well as effective logistic
392	(vaccine transport, storage, and continuous cold-chain monitoring) are key factors for
393	a successful mass vaccination campaign.
394	
395	In the early phase of COVID-19 spread in Wuhan in 2019, before interventions were

put in place,  $R_0$  was estimated to be in the range 2.0-3.5<sup>27-32</sup>. Given the knowledge of mechanisms of SARS-CoV-2 transmission, and the devastating consequences of an uncontrolled COVID-19 epidemic, the Chinese population would hold a precautious behavior (such as clean hands often, cough or sneeze in bent elbow, avoid close

400	contact with someone who is sick, etc.) even without the need to impose NPIs. As
401	such, in our analysis simulating an epidemic triggered by imported cases, we decided
402	to consider an initial R of 2.5, which is at the lower end of the estimated spectrum.
403	
404	SARS-CoV-2 variants are circulating globally and quickly became dominant in
405	countries like the UK and Italy (lineage B.1.1.7), and South Africa (lineage B.1.351).
406	Recently, a variant B.1.617 identified in India has raised global concern. As of May 7,
407	2021, Mainland China border control screenings have already identified imported
408	cases with SARS-CoV-2 lineage B.1.1.7 and B.1.617. Our study shows that the spread
409	of new more transmissible and/or more lethal variants could substantially decrease the
410	net benefit of vaccination. Strict border quarantine and isolation as well as genomic
411	surveillance will be key while vaccines roll out in China.
411 412	surveillance will be key while vaccines roll out in China.
411 412 413	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the
411 412 413 414	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the
<ul> <li>411</li> <li>412</li> <li>413</li> <li>414</li> <li>415</li> </ul>	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a
<ul> <li>411</li> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> </ul>	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a nation-wide rollout will likely include a combination of vaccines with varying
<ul> <li>411</li> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> </ul>	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a nation-wide rollout will likely include a combination of vaccines with varying efficacy, monitoring vaccine effectiveness on the ground will remain a priority.
<ul> <li>411</li> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> <li>418</li> </ul>	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a nation-wide rollout will likely include a combination of vaccines with varying efficacy, monitoring vaccine effectiveness on the ground will remain a priority.
<ul> <li>411</li> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> <li>418</li> <li>419</li> </ul>	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a nation-wide rollout will likely include a combination of vaccines with varying efficacy, monitoring vaccine effectiveness on the ground will remain a priority. Here we propose a general framework to evaluate the impact of COVID-19
<ul> <li>411</li> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> <li>418</li> <li>419</li> <li>420</li> </ul>	surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a nation-wide rollout will likely include a combination of vaccines with varying efficacy, monitoring vaccine effectiveness on the ground will remain a priority. Here we propose a general framework to evaluate the impact of COVID-19 vaccination programs in the absence/presence of NPIs and to explore priority target

422	framework is adaptable to other country-specific contexts. However, it requires the
423	collection of country-specific data about the epidemiological situation (e.g., landscape
424	immunity of the local population, prevalence of infections), vaccination parameters
425	(e.g., vaccine supply and capacity of immunization services, efficacy of different
426	vaccines, target age groups), socio-demographic characteristics of the population (e.g.,
427	size of the priority population by age group, age-mixing patterns), and the priorities of
428	the pandemic responses (e.g., limit the death toll, prevent infections).
429	
430	Our study has a number of limitations. First, we integrated the impact of NPIs through
431	a simple reduction in the value of $R_t$ at the beginning of the outbreak, homogeneously
432	across age groups. However, our analysis does not suggest which combination of
433	NPIs should be adopted to lower $R_t$ to a certain level, and how this would affect
434	transmission rates in different age groups. Li, et al, estimated that individual NPIs,
435	including school closure, workplace closure, and public events bans, were associated
436	with reductions in $R_t$ of 13–24% on day 28 after their introduction <sup>53</sup> . Further studies
437	are needed to pinpoint the specific NPIs to be adopted in parallel with the vaccination
438	campaign and their impact on the quality of life of the population.
439	
440	Second, in China, vaccines have not been licensed for children, so we assume a 50%
441	lower or equivalent VE for them compared to other adults. Although we show that
442	variations in these rates do not substantially affect the overall effect of the vaccination
443	campaign, further data on age-specific vaccine efficacy could help refine priority

444	groups. Our sensitivity analyses on vaccine coverage reveal the importance of
445	extending the vaccination to the young population once the use of vaccines will be
446	authorized for that age segment of the population.
447	
448	Third, we assumed that immunity after natural infections lasts more than the time
449	horizon considered (two years). If this is not the case, waning of immunity would
450	inflate the rate of susceptible individuals and thus require booster vaccinations. This
451	could become an issue with the emergence of immune-escape variants, as reported in
452	South Africa <sup>54</sup> . Given limited information at this stage, we did not consider this
453	scenario in our analyses, but this is an important area of future research.
454	
454 455	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals
454 455 456	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we
454 455 456 457	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19
454 455 456 457 458	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also
454 455 456 457 458 459	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also performed a sensitivity analysis based on the mixing patterns estimated in China in
454 455 456 457 458 459 460	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also performed a sensitivity analysis based on the mixing patterns estimated in China in March 2020 <sup>50</sup> , after the lockdown was lifted but schools were still closed. How the
454 455 456 457 458 459 460 461	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also performed a sensitivity analysis based on the mixing patterns estimated in China in March 2020 <sup>50</sup> , after the lockdown was lifted but schools were still closed. How the population would mix in case of a new wave of COVID-19 starts to unfold in China
454 455 456 457 458 459 460 461 462	Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also performed a sensitivity analysis based on the mixing patterns estimated in China in March 2020 <sup>50</sup> , after the lockdown was lifted but schools were still closed. How the population would mix in case of a new wave of COVID-19 starts to unfold in China remains to be seen.

464 Moreover, our study is performed at a national scale and thus our estimates of the 465 impact of vaccination should be interpreted cautiously at the local scale. In fact,

466 spatial heterogeneities within China in terms of risk of case importation,

- 467 socio-demographic characteristics of the population, mixing and mobility patterns,
- 468 vaccination coverage and capacity may affect our results.
- 469

470	Enhanced	vaccination	efforts i	n conj	unction	with	NPIs	have	been	successfully	used
-----	----------	-------------	-----------	--------	---------	------	------	------	------	--------------	------

- 471 during the COVID-19 outbreak in Ruili city (Yunnan Province, China) in March-April,
- 472 2021. Our analysis, however, focuses on the assessment of whether and to what extent
- 473 we need to rely on NPIs to prevent a COVID-19 epidemic while vaccines are rolled
- 474 out. As such, our results cannot be used to guide a reactive spatially targeted strategy.
- To properly capture the peculiarity of that context, specific modeling tools mirroring
- the interventions adopted in China as a response to emerging outbreaks are needed.
- 477
- 478 Finally, it would be interesting to analyze adaptive vaccination prioritizations that
- 479 changes as the epidemiological situation evolves over time but that would require the
- 480 development of dynamic optimization algorithms that are beyond the scope of this
- work <sup>55</sup>. Nonetheless, our study provides estimates of the effect of relaxing NPIs over
  the course of the epidemic.
- 483

In conclusion, vaccination alone could substantially reduce COVID-19 burden, but in the foreseeable future may not be enough to prevent local outbreaks to escalate to major widespread epidemics due to limitation in the vaccine production and supply (particularly at the initial stage of the vaccination), as well as the capacity of

488 vaccination system. This is especially relevant in contexts where most	t of the	ıe
--	----------	----

- 489 population is still susceptible to SARS-CoV-2 infection, as it is the case in most of
- 490 China. Maintaining NPIs (such as social distancing, testing, case isolation and contact
- 491 tracing, wearing masks, and limitation on large gatherings) throughout 2021 is
- 492 necessary to prevent the resurgence of COVID-19 epidemics until a sufficiently high
- 493 level of immunity is reached, which depends on the transmissibility of the variants
- 494 circulating at that time.



# 495 Figure legend



497 Figure 1. Time series of symptomatic cases, effective reproductive number R<sub>t</sub>,

## 498 and population infected and vaccinated.

a) Number of symptomatic cases over time as estimated in the no-NPIs scenario

500	(initial $R_t=2.5$ ) in the absence/presence of vaccination. b) Net reproduction number $R_t$
501	over time, as estimated using a Bayesian framework (Supplementary File 6) from the
502	time series of symptomatic cases in the no-NPIs scenario in the presence of
503	vaccination. The horizontal line indicates the epidemic threshold $R_t=1$ and the vertical
504	line indicates where $R_t$ cross this threshold. Note that for the first few generations of
505	cases, $R_t$ shows an increasing pattern linked to the highly stochastic nature of
506	epidemics in their initial phase when epidemics with initially larger $R_t$ are more likely
507	to survive <sup>56</sup> . c) Absolute numbers and proportion of the Chinese population infected
508	and vaccinated over time in the no-NPIs scenario in the presence of vaccination. The
509	population size of China in 2020 is 1,439,324,000 <sup>57</sup> . d)-f): as a-c but for the mild
510	NPIs scenario (initial $R_t=1.5$ ). g)-i): as a-c but for the moderate NPIs scenario (initial
511	R <sub>t</sub> =1.3); j)-l): As a-c but for the high NPIs scenario (initial R <sub>t</sub> =1.1). Line denotes
512	median, and shadow denotes quantiles 0.025 and 0.975.



514

## 515 Figure 2. Burden of COVID-19 in the main analysis.

a) Cumulative number of symptomatic cases as estimated under the different scenarios in the absence/presence of vaccination over the simulated 2-year period. No vaccination + no NPIs with  $R_t=2.5$  at the beginning of the outbreak is called *reference scenario*, described using dark brown bars. Light yellow bars indicate scenarios including vaccination and/or different levels of NPIs. b) Reduction in the cumulative number of symptomatic cases with respect to the *reference scenario*. Orange bars and black values indicate the contribution of NPIs, blue bars and black values indicate the

513

- 523 overall contribution of vaccination and NPIs, while the white values indicate net
- 524 contribution of vaccination; c)-d) As a-b but for hospitalized cases; e)-f) As a-b but for
- 525 cases admitted to ICU; g)-h) As a-b but for deaths. Number denotes median, and error
- 526 bars denote quantiles 0.025 and 0.975.



# 527

#### 528 Figure 3. Impact of daily vaccine administration capacity on COVID-19 deaths.

a) Cumulative number of COVID-19 deaths (millions) as estimated in the different

530 scenarios under progressively increasing values of the daily vaccination capacity; b)

531 Proportion of deaths averted compared to the *reference scenario*, i.e., *no vaccination* 

532 + no NPIs with R<sub>t</sub>=2.5 at the beginning of the outbreak. Number denotes median, and

error bars denote quantiles 0.025 and 0.975.





Initial cases denote breakthrough COVID-19 cases, which initiates the epidemic. We
consider the impact of uncertainty (i.e., "Yes" in the figure, which means 200
stochastic model realizations are performed in order to account for the ranges) in
contact patterns and relative susceptibility on prioritization, and use their mean values
as well (i.e., No). Baseline denotes first prioritizing older adults and individuals with

- 541 underlying conditions. Number in the box denotes the death toll (median), with t
- 542 representing thousand and m representing million. Minimum denotes the lowest
- 543 deaths in each scenario on the basis of median value. We compare other strategies to
- that with minimum deaths using rank sum test. E.g., in the context of initial
- 545 cases=5,000, R<sub>t</sub>=1.5 and using mean values of contact patterns and relative
- 546 susceptibility, the baseline is the optimal strategy to minimize deaths.

## 547 Methods

#### 548 SARS-CoV-2 transmission and vaccination models

- 549 We developed a model of SARS-CoV-2 transmission and vaccination, based on an
- 550 age-structured stochastic susceptible-infectious-removed (SIR) scheme, accounting
- 551 for heterogeneous mixing patterns by age as estimated in Shanghai<sup>13</sup>. The Chinese
- 552 population was distributed in 18 age groups (17 5-year age groups from 0 to 84 years
- and one age group for individuals aged 85 years or older)  $5^{7}$ . Each age group was
- 554 further split into two subgroups: individuals with or without underlying conditions,
- s55 where the former was considered to be associated with an increased risk of severe
- 556 outcome of COVID-19  $^{14}$ .
- 557

567

558 In the main analysis, susceptibility to SARS-CoV-2 infection was assumed to be 559 heterogeneous across ages. Children under 15 years of age were considered less 560 susceptible to infection compared to adults aged 15 to 65 years, while the older adults more susceptible <sup>33,34</sup>. Homogeneous susceptibility across age groups was explored in 561 562 sensitivity analysis (SA19). Asymptomatic and symptomatic individuals were assumed to be equally infectious <sup>33,34</sup>, and infectiousness was also assumed to be the 563 564 same across age groups <sup>33,34</sup>. 565 566 Vaccine is administered with a two-dose schedule. In the baseline model, we assumed

susceptible individuals are eligible for vaccination, i.e., we excluded all individuals

that: i) vaccination reduces susceptibility to SARS-CoV-2 infection; ii) only

<b>F</b> OO	4141			0 0-	110	· · · · · · · · · · · ·	:::>	1	- f	!	·
569	that have ex	periencec	I SAK	S-C0	) V-2	infection:	111)	duration	OI V	accine-	induced
							· /				

- 570 protection lasts longer than the time horizon considered (2 years).
- 571 The baseline model is schematically represented in Supplementary Fig.1 and it is
- 572 described by differential systems presented in Supplementary File 1-2.
- 573

## 574 Model initialization

- 575 In China, the first pandemic wave of COVID-19 was controlled by intense NPIs <sup>58,59</sup>.
- 576 Almost the entire population of mainland China is still susceptible to COVID-19 $^3$ . As
- 577 such, the model is initialized with a fully susceptible population.

578

- 579 China has been facing mounting pressure of imported COVID-19 cases. Containment
- 580 of COVID-19 has been possible only through a combination of measures such as
- 581 complete- or partial-lockdown, citywide mass-screening using
- 582 reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing, tracing of contacts
- and contacts of contacts of COVID-19 cases, which were promptly applied wherever
- 584 COVID-19 transmission has popped up in mainland China <sup>60</sup>. Despite all the efforts,
- 585 containment of COVID-19 appears a whack-a-mole game and sporadic outbreaks
- 586 inevitably occur. Simulations are thus initialized with 40 cases, roughly corresponding
- to the number of cases with symptoms onset in Beijing before the detection of a local
- 588 outbreak in June 11, 2020<sup>61</sup>.

589

#### 590 Vaccination scenarios

591	To explore the impact of vaccination, we ran a set of simulations in which neither
592	NPIs nor vaccination are implemented as a <i>reference scenario</i> (no vax + no NPIs, i.e.,
593	effective reproductive number $R_t$ =2.5 at the beginning of simulations <sup>17,28,58</sup> ), and
594	compared it with a scenario in which vaccination only is implemented ( $vax + no$
595	NPIs). Further, we considered different sets of simulations in which NPIs are used to
596	bring $R_t$ respectively down to 1.5 (mild NPIs), 1.3 (moderate NPIs), and 1.1 (high
597	NPIs), with ( <i>vax</i> + <i>mild/moderate/high</i> NPIs) or without vaccination program ( <i>no</i> vax
598	+ mild/moderate/high NPIs). In the main analysis vaccination is assumed to begin 15
599	days after the epidemic start. Alternative scenarios about the seeding of the epidemic
600	were explored as sensitivity analyses. In particular, we considered the epidemic to
601	start when 10% (SA1), 20% (SA2), and 30% (SA3) of the Chinese population has
602	already been vaccinated.
603	
604	The model is run considering daily time steps. Gradual delivery of vaccine doses is

605 implemented by vaccinating a fixed number of individuals each day. Although

606 manufacturers state that a total of 3.9 billion doses of vaccines could be available by

607 the end of  $2021^{22-26}$ , scale-up and delivery will take months. On the basis of the 2009

608 H1N1 influenza pandemic vaccination program implemented in mainland China<sup>62</sup>, in

the main analysis we assumed 6 million doses of COVID-19 vaccines could be

administered each day (4 doses per 1,000 individuals) until uptake reaches 70% for all

611 groups <sup>14</sup>. Different values of the daily vaccine administration capacity, i.e., 1.3

612 (SA20), 10 (SA21), 15 (SA22), 30 (SA23) million dose per day, are explored in

613 separate sensitivity analyses. Sensitivity analyses were also performed on the

- 614 vaccination coverage which is assumed either to be homogenous  $(SA4 \text{ and } SA5)^{14}$  or
- 615 heterogeneous by age (*SA6*, *SA7*, and *SA8*).
- 616
- 617 In the main analysis, vaccination is administered to susceptible individuals only. This
- 618 represents an ideal scenario where we assume that all infected individuals can be
- 619 identified (e.g., either via RT-PCR while infected or via serological assays later one)
- and that SARS-CoV-2 infection confers a long-lasting immunity. Since infection
- ascertainment could be challenging and pose additional strain to the health system, we
- also consider two sensitivity analyses in which only detected symptomatic cases are
- 623 excluded from vaccination (*SA14-SA15*).
- 624

625 In the context of fast RT-PCR-based mass screening if there is an outbreak,

under-ascertainment of symptomatic cases could be only related with the sensitivity

627 of RT-PCR tests. The sensitivity is quite high (98%) if the interval between symptom

onset and RT-PCR test is within 7 days, and the sensitivity decreases to 68% if the

- time interval is  $8-14 \text{ days}^{63}$ . The mean time interval from symptom onset to the date
- 630 of collection of the sample for PCR testing was estimated to be  $4.7 \text{ days in Hunan}^{33}$ .
- 631 Accordingly, we considered as ascertainment probabilities of symptomatic cases 70%
- 632 (*SA14*) and 90% (*SA15*).

633

634 Vaccination schedule and efficacy

635	There are six COVID-19 vaccines developed by China in phase 3 clinical trials,
636	including five vaccines administered with a two-dose schedule with an interval of 14,
637	21, or 28 days and one single-dose recombinant adenovirus type-5-vectored vaccine.
638	For simplicity, in the main analysis, we modeled the administration of an inactivated
639	vaccine developed by the Beijing Institute of Biological Products, <sup>64</sup> which entail a
640	two-dose schedule across all age groups with an interval of 21 days. In separate
641	sensitivity analyses, we explored an interval of 14 days and 28 days (SA16-SA17).
642	
643	China approved its first local COVID-19 vaccine (developed by Sinopharm) for
644	general public use on December 31, 2020, with an estimated vaccine efficacy (VE) of
645	79.3%. <sup>21</sup> In the main analysis, we used a VE of 80% against infection in individuals
646	aged 20-59 years. In the developed model, vaccination confers a partial protection, i.e.,
647	vaccinated individuals are 80% less likely to develop infection upon an infectious
648	contact. Sensitivity analyses using a VE of 60% (SA9) and 90% (SA10) were
649	separately performed. The alternative values of VE were selected on the basis of
650	published upper efficacy of vaccines of 94-95% and in such a way to cover a
651	plausible efficacy range of forthcoming vaccines <sup>65-67</sup> .
652	
653	Phase 2 clinical trials demonstrated that vaccine immunogenicity was lower among
654	older individuals than in younger adults <sup>64</sup> . And for other inactivated vaccines like
655	influenza vaccine, a lower VE is observed in children compared to young adults <sup>68</sup> .

656 Accordingly, we assumed an age-dependent VE. In particular, given a baseline

657	efficacy VE among individuals aged 20-59 years (80% in the main analysis), we
658	assumed a 50% lower VE in individuals <20 and $\geq$ 60 years of age (namely 40%). A
659	scenario without age-specific variations in VE was explored as sensitivity analysis
660	( <i>SA24</i> ).
661	
662	Individuals vaccinated with the first dose could still develop infections without any
663	immune protection, while the second dose vaccination could produce the expected
664	vaccine efficacy after an average of 14 days. In the main analysis we assume both
665	natural infection-induced and vaccine-induced immunity to SARS-CoV-2 infection
666	does not wane within the considered time horizon (2 years). In additional sensitivity
667	analyses, we considered an average duration of vaccine-induced protection of 6
668	months (SA12) and 1 year (SA25). We also consider a sensitivity analysis assuming
669	that vaccination is effective in preventing symptomatic illness, but not infection
670	(SA11), and another one assuming an all-or-nothing vaccine, i.e., the vaccine confers
671	full protection to VE percent of vaccinated individuals (SA18).
672	
673	Priority order of vaccination
674	The doses available to be distributed daily (6 million in the main analysis) are

assigned by considering the following order of priority  $^{14}$ . In the main analysis,

- healthcare workers are considered as the top priority (Tier 1 of the vaccination
- 677 strategy); law enforcement and security workers, personnel in nursing home and
- 678 social welfare institutes, community workers, workers in energy, food and

679	transportation sectors are included in Tier 2; adults $\geq$ 60 years of age with underlying
680	conditions, and adults $\geq$ 80 years of age without underlying conditions, who are at the
681	highest risk of severe/fatal COVID-19, are considered in Tier 3; individuals aged < 60
682	years with pre-existing medical conditions and pregnant women are included in Tier 4;
683	individuals aged 20-59 years without underlying conditions are included in Tier 5;
684	school-age children and younger children aged $\leq 5$ years without underlying
685	conditions are recommended for vaccination in Tier 6 (Supplementary File 4).
686	
687	Different priority orders are explored as sensitivity analyses. Healthcare workers and
688	the other essential workers listed above are fixed in Tier 1 and Tier 2 of vaccination,
689	while the remaining population is vaccinated as described in Supplementary Table 2
690	by considering different orders of prioritization only based on age and disregarding
691	the presence of underlying conditions (SA26: first prioritization to old adults; SA27:
692	first prioritization to working-age groups; SA28: first prioritization to school-age
693	groups). We explore the impact of 5,000 initial cases on the prioritization strategy
694	(SA29). To understand the impact in terms of number of infections by age, we
695	compare the prioritization strategy when we account for the uncertainty in the contact
696	matrix and in the susceptibility to infection by age, or not (in this context, median
697	values of contact numbers and relative susceptibility are used).
698	
699	COVID-19 burden model

700 The main output of above transmission model is the age-specific number of new

701	infections per day in the subpopulation with or without underlying conditions. On top
702	of that, we developed a model of COVID-19 disease burden to estimate the number of
703	symptomatic cases, hospitalization, ICU admissions, and deaths in different scenarios
704	in the presence/absence of vaccination.
705	
706	We computed the age-specific number of symptomatic infections in individuals with
707	and without underlying conditions on a daily-basis, by applying an age-specific
708	probability of respiratory symptoms, which is 18.1%, 22.4%, 30.5%, 35.5%, and 64.6%
709	separately for 0-19, 20-39, 40-59, 60-79, and 80+ years of age, as estimated from
710	contact tracing data in Lombardy $^{20}$ . We assume that individuals with and without
711	underlying conditions have the same age-specific probability of developing
712	symptoms.
713	
714	The daily age-specific number of hospital admissions in the two subpopulations was
715	computed by applying the age-specific proportion of laboratory-confirmed
716	symptomatic cases requiring hospitalizations (Supplementary File 5), delayed by an
717	average time of 3.8 days between symptom onset and hospitalization <sup>17</sup> .
718	The daily age-specific number of patients admitted to ICU in the two subpopulations
719	was computed by applying to hospitalized cases an age-specific probability of being
720	admitted to ICU <sup>19</sup> , and distinguishing patients requiring intensive care in survivors
721	and non-survivors. Survivors are admitted to ICU after an average time of 7 days
722	from hospitalization. Non-survivors are admitted to ICU after an average time of 8

723 days after hospitalization  $^{16}$ .

724

725	The daily age-specific number of deaths in the two subpopulations was computed by
726	applying the age-specific fatality ratio among symptomatic cases (Supplementary File
727	5), delayed by an average time of 13.9 days between symptom onset and death $^{18}$ .
728	
729	Data analysis
730	For each scenario, 200 stochastic model realizations were performed. The outcome of
731	these simulations determined the distributions of the number of symptomatic
732	infections, hospitalizations, ICU admissions, and deaths. 95% confidence intervals
733	were defined as quantiles 0.025 and 0.975 of the estimated distributions. We used a
734	Bayesian approach to estimate $R_t$ from the time series of symptomatic cases by date
735	of symptom onset and the distribution of the serial interval <sup>17</sup> . The methods were
736	described in Supplementary File 6 in details.
737	
738	Ethics approval All these data were in the public domain. Ethical review for the
739	re-use of these secondary data is not required.
740	
741	Reporting summary
742	Further information on research design is available in the Nature Research Reporting
743	Summary linked to this paper.
744	

# 745 Data and code availability

746 Should the manuscript be accepted, all data and codes will be provided on *GitHub*.

# 747 References

748	1.	Johns Hopkins University Coronavirus Research Center. New cases of COVID-19 in
749		world. https://coronavirus.jhu.edu/data/new-cases (2021).
750	2.	Zhao, J. et al. Disease Burden Attributable to the First Wave of COVID-19 in China
751		and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies.
752		<i>Value Health</i> <b>24</b> , 615-624 (2021).
753	3.	Chen, X. et al. Serological evidence of human infection with SARS-CoV-2: a
754		systematic review and meta-analysis. <i>Lancet Glob Health</i> <b>9</b> , e598-e609 (2021).
755	4.	Our World in Data. Coronavirus (COVID-19) Vaccinations.
756		https://ourworldindata.org/covid-vaccinations (2021).
757	5.	Wang, W. et al. Global, regional, and national estimates of target population sizes for
758		covid-19 vaccination: descriptive study. <i>BMJ</i> <b>371</b> , m4704 (2020).
759	6.	Press Conference of the Joint Prevention and Control Mechanism of the State
760		Council. Introduction to the promotion of COVID-19 vaccination (Up to May 7).
761		http://www.gov.cn/xinwen/2021-05/08/content_5605360.htm (2021).
762	7.	National Health Commission of the People's Republic of China. Outbreak report.
763		http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml (2021).
764	8.	Anderson, R.M. & May, R.M. Vaccination and herd immunity to infectious diseases.
765		<i>Nature</i> <b>318</b> , 323-329 (1985).
766	9.	Agur, Z., Cojocaru, L., Mazor, G., Anderson, R.M. & Danon, Y.L. Pulse mass measles
767		vaccination across age cohorts. <i>Proc Natl Acad Sci U S A</i> 90, 11698-11702 (1993).
768	10.	Chao, D.L., Halloran, M.E. & Longini, I.M., Jr. Vaccination strategies for epidemic

769	cholera in Haiti	with implications	s for the developing	a world. <i>Pre</i>	oc Natl Acad Sci	USA
	•					

- 770 **108**, 7081-7085 (2011).
- 11. Ferguson, N.M., Donnelly, C.A. & Anderson, R.M. The foot-and-mouth epidemic in
- 772 Great Britain: pattern of spread and impact of interventions. *Science* 292, 1155-1160
- 773 (2001).
- 12. Wu, J.T., Peak, C.M., Leung, G.M. & Lipsitch, M. Fractional dosing of yellow fever
- vaccine to extend supply: a modelling study. *Lancet* **388**, 2904-2911 (2016).
- TT6 13. Zhang, J. et al. Patterns of human social contact and contact with animals in
- 777 Shanghai, China. *Sci Rep* **9**, 15141 (2019).
- 778 14. Yang, J. et al. Who should be prioritized for COVID-19 vaccination in China? A
- 779 descriptive study. *BMC Med* **19**, 45 (2021).
- 780 15. Yang, J. et al. Disease burden and clinical severity of the first pandemic wave of

781 COVID-19 in Wuhan, China. *Nat Commun* **11**, 5411 (2020).

- 782 16. Xie, J. et al. Clinical characteristics and outcomes of critically ill patients with novel
- 783 coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study.
- 784 Intensive Care Med 46, 1863–1872 (2020).

785 17. Zhang, J. et al. Evolving epidemiology and transmission dynamics of coronavirus

786 disease 2019 outside Hubei province, China: a descriptive and modelling study.

- 787 *Lancet Infect Dis* **20**, 793-802 (2020).
- 788 18. Deng, X. et al. Case fatality risk of the first pandemic wave of novel coronavirus

disease 2019 (COVID-19) in China. *Clin Infect Dis*, ciaa578 (2020).

790 19. Guan, W. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl

- 791 *J Med* **382**, 1708-1720 (2020).
- 792 20. Poletti, P. et al. Association of Age With Likelihood of Developing Symptoms and
- 793 Critical Disease Among Close Contacts Exposed to Patients With Confirmed
- SARS-CoV-2 Infection in Italy. *JAMA Netw Open* **4**, e211085 (2021).
- 795 21. Sinopharm. Sinopharm COVID-19 vaccine licensed in China.
- 796 http://www.sinopharm.com/s/1223-3763-38840.html (2021).
- 797 22. CNWest. Curret development and production capacity of domestic COVID-19 vaccine.
- 798 http://news.cnwest.com/szyw/a/2020/12/04/19343015.html (2021).
- 799 23. Huanqiu Net. Chairman of Cansino Bio: After the increase in production capacity, the
- 800 company's COVID-19 vaccine will be released in large quantities.
- 801 https://baijiahao.baidu.com/s?id=1692936657439211781&wfr=spider&for=pc (2021).
- 802 24. Sinopharm. The first batch of BBIBP-CorV(Sinopharm) has shipped.
- 803 http://www.sinopharm.com/s/1223-3769-39020.html (2021).
- 804 25. Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will
- 805 reach 2 billion doses by June.
- 806 https://cn.reuters.com/article/sinovac-biotech-covid-vaccine-0303-idCNKCS2AV0DL
- 807 (2021).
- 808 26. Sinopharm. Chinese and foreign media enter the 1 billion-level COVID-19 vaccine
- production base. http://www.sinopharm.com/s/1223-4126-39018.html (2021).
- 810 27. Wu, J.T., Leung, K. & Leung, G.M. Nowcasting and forecasting the potential domestic
- 811 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
- 812 modelling study. *Lancet* **395**, 689-697 (2020).

813	28.	Li, Q. et al. Early	Transmission D	ynamics in Wuhan,	China, of Novel
					,

- 814 Coronavirus–Infected Pneumonia. N Engl J Med 382, 1199-1207 (2020).
- 815 29. Abbott, S., Hellewell, J., Munday, J., group, C.n.w. & Funk, S. The transmissibility of
- 816 novel Coronavirus in the early stages of the 2019-20 outbreak in Wuhan: Exploring
- 817 initial point-source exposure sizes and durations using scenario analysis. *Wellcome*
- 818 *Open Res* **5**, 17 (2020).
- 819 30. Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel
- 820 coronavirus (COVID-19) outbreak. *Science* **368**, 395-400 (2020).
- 821 31. Natsuko, I. et al. Report 3: Transmissibility of 2019-nCoV. Imperial College London.
- 822 https://doi.org/10.25561/77148 (2020)
- 823 32. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus
- 824 Disease 2019 (COVID-19).
- 825 https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coron
- 826 <u>avirus-disease-2019-(covid-19)</u> (2021).
- 827 33. Hu, S. et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2
- 828 transmission under intensive contact tracing in Hunan, China. Nature
- 829 *Communications* **12**, 1533 (2021).
- 830 34. Sun, K. et al. Transmission heterogeneities, kinetics, and controllability of
- 831 SARS-CoV-2. *Science*, eabe2424.
- 832 35. Li, L. et al. Influenza-associated excess respiratory mortality in China, 2010-15: a
- 833 population-based study. *The Lancet. Public health* **4**, e473-e481 (2019).
- 834 36. Wang, J. et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic

835		in China. <i>Vaccines</i> <b>8</b> , 482 (2020).
836	37.	Wang, J. et al. The Changing Acceptance of COVID-19 Vaccination in Different
837		Epidemic Phases in China: A Longitudinal Study. Vaccines (Basel) 9(2021).
838	38.	Shao, G., Ding, W., Yu, Y., Ma, H. & Zhijie, A. Willingness of parents to vaccinate
839		family members with coronavirus disease 2019, influenza, and pneumococcal
840		vaccines, Anyang city, May to June 2020. Chinese Journal of Vaccines and
841		Immunization (2020).
842	39.	SINOVAC. Supply Vaccines to Eliminate Human Diseases.
843		http://www.sinovac.com.cn/?optionid=468&auto_id=1877 (2021).
844	40.	CanSinoBIO. The application for conditional marketing of CansinoBio Coronavirus
845		Vaccine ConvideciaTM was accepted by the National Medical Products
846		Administration. http://www.cansinotech.com.cn/html/1///179/180/806.html (2021).
847	41.	Beijing Institute of Biological Products Co., LTD. Products Instruction.
848		https://www.bjbpi.com/?p=75 (2021).
849	42.	Palacios, R. et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in
850		Healthcare Professionals in Brazil: The PROFISCOV Study. Preprint at SSRN
851		https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780 (2021).
852	43.	Wuhan Institute of Biological Products Co., LTD. The interim analysis data of the
853		COVID-19 inactivated vaccine phase III clinical trial of Sinopharm Wuhan Institute of
854		Biological Products released. <u>http://www.wibp.com.cn/Chs/Detail.aspx?Id=14669</u>
855		(2021).
856	44.	Centers for Disease Control and Prevention. About Variants of the Virus that Causes

### 857 COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html

- 858 (2021).
- 45. Davies, N.G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage
- 860 B.1.1.7 in England. *Science*, eabg3055 (2021).
- 861 46. Stefanelli, P. et al. Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1. Preprint at
- 862 *medRxiv* https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1 (2021).
- 863 47. Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of
- 864 concern 202012/1: matched cohort study. *BMJ* 372, n579 (2021).
- 865 48. Davies, N.G. et al. Increased mortality in community-tested cases of SARS-CoV-2
- 866 lineage B.1.1.7. *Nature* (2021).
- 49. Meehan, M.T. et al. Age-targeted dose allocation can halve COVID-19 vaccine
- 868 requirements. Preprint at *medRxiv*
- 869 https://www.medrxiv.org/content/10.1101/2020.10.08.20208108v2 (2020).
- 870 50. Zhang, J. et al. The impact of relaxing interventions on human contact patterns and
- 871 SARS-CoV-2 transmission in China. *Science Advances* 7, eabe2584 (2020).
- 872 51. Bubar, K.M. et al. Model-informed COVID-19 vaccine prioritization strategies by age
- 873 and serostatus. *Science* **371**, 916-921 (2021).
- 52. Giordano, G. et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the
- 875 requirement for non-pharmaceutical interventions in Italy. *Nat Med* (2021).
- 53. Li, Y. et al. The temporal association of introducing and lifting non-pharmaceutical
- 877 interventions with the time-varying reproduction number (R) of SARS-CoV-2: a
- modelling study across 131 countries. *Lancet Infect. Dis.* **21**, 193-202 (2021).

- 879 54. Wibmer, C.K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African
- 880 COVID-19 donor plasma. Preprint at *bioRxiv*
- 881 http://biorxiv.org/content/early/2021/01/19/2021.01.18.427166.abstract (2021).
- 882 55. Han, S. et al. Dynamic optimization of COVID-19 vaccine prioritization in the context of
- 883 limited supply. Preprint at *Nature Portfolio*
- 884 https://www.researchsquare.com/article/rs-257573/v1 (2021).
- 885 56. Liu, Q.H. et al. Measurability of the epidemic reproduction number in data-driven
- 886 contact networks. *Proc Natl Acad Sci U S A* **115**, 12680-12685 (2018).
- 887 57. Population Division, Department of Economic and Social Affairs, United Nations.
- 888 World Population Prospects 2019. https://population.un.org/wpp/ (2019).
- 889 58. Pan, A. et al. Association of Public Health Interventions With the Epidemiology of the
- 890 COVID-19 Outbreak in Wuhan, China. *JAMA* **323**, 1915-1923 (2020).
- 891 59. Li, Z. et al. Active case finding with case management: the key to tackling the
- 892 COVID-19 pandemic. *Lancet* **396**, 63-70 (2020).
- 893 60. Xing, Y., Wong, G.W.K., Ni, W., Hu, X. & Xing, Q. Rapid Response to an Outbreak in
- 894 Qingdao, China. *N Engl J Med* **383**, e129 (2020).
- 895 61. Xinhua net. The COVID-19 outbreak in Beijing.
- 896 http://www.xinhuanet.com/politics/2020-06/19/c\_1126135352.htm (2020).
- 897 62. The Central People's Government of the People's Republic of China. Report of H1N1
- 898 pandemic influenza vaccination from Ministry of Health. http://www.gov.cn/gzdt
- 899 (2020).
- 900 63. Xiao, A. et al. Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in

- 901 Wuhan, China: A Descriptive Study. Journal of Clinical Virology 127, 104346 (2020).
- 902 64. Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,
- 903 BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet
- 904 *Infect Dis* **21**, 39-51 (2021).
- 905 65. Callaway, E. COVID vaccine excitement builds as Moderna reports third positive
- 906 result. *Nature* **587**, 337-338 (2020).
- 907 66. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
- 908 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
- 909 South Africa, and the UK. *Lancet* **397**, 99-111 (2021).
- 910 67. Polack, F.P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N
- 911 *Engl J Med* **383**, 2603-2615 (2020).
- 912 68. Yang, P. et al. Influenza vaccine effectiveness against medically-attended influenza
- 913 illness during the 2012-2013 season in Beijing, China. Vaccine 32, 5285-5289 (2014).
- 914

## 915 End notes

#### 916 Acknowledgments

- 917 The study was supported by grants from the National Science Fund for Distinguished
- 918 Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and
- 919 Technology Committee (No 20411950100), European Union Grant 874850 MOOD
- 920 (MOOD 000).

921

## 922 Author Contributions

- 923 H.Y. conceived the study. H.Y., S.M., and M.A. designed and supervised the study.
- 924 J.Y., J. Z., J.C., W.W., Q.W., W.Z., Z.Z, K.D., and G.Z. participated in data collection.
- 925 V.M., G.G., P.P., and F.T. developed the model. V.M., J.Y., and X.D. analyzed the
- 926 model outputs and prepared the tables and figures. J.Y. prepared the first draft of the
- 927 manuscript. H.Y., V.M., and M.A. commented on the data and its interpretation,
- 928 revised the content critically. All authors contributed to review and revision and
- 929 approved the final manuscript as submitted and agree to be accountable for all aspects
- 930 of the work.
- 931

## 932 Declaration of interests

- 933 H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang
- 934 HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical
- 935 Company. M.A. has received research funding from Seqirus. None of those research
- 936 funding is related to COVID-19. All other authors report no competing interests.

## 937

## 938 Disclaimer

- 939 This article does not necessarily represent the views of the NIH or the US
- 940 government.
- 941

#### 942 Additional information

- 943 **Supplementary Information** is available for this paper.
- 944 **Correspondence and requests for materials** should be addressed to M.A., and H.Y.
- 945 **Peer review information.**

946	Reprints	and	permissions	information	is	available	at

947 http://www.nature.com/reprints.